Illuminating Hope for Mental Health: A Drug Review on Lumateperone.
| Autor: | Tarzian M; Psychiatry, University of Medicine and Health Sciences, Basseterre, KNA., Ndrio M; Psychiatry and Behavioral Sciences, University of Medicine and Health Sciences, Basseterre, KNA., Chique B; Surgery, University of Medicine and Health Sciences, Basseterre, KNA., Serai J; Medicine, University of Medicine and Health Sciences, Basseterre, KNA., Thalackal B; Medicine, University of Medicine and Health Sciences, Basseterre, KNA., Lau J; Human Health, University of Guelph, Guelph, CAN., Fakoya AO; Cellular Biology and Anatomy, Louisiana State University Health Sciences Center, Shreveport, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2023 Sep 28; Vol. 15 (9), pp. e46143. Date of Electronic Publication: 2023 Sep 28 (Print Publication: 2023). |
| DOI: | 10.7759/cureus.46143 |
| Abstrakt: | This drug review provides a comprehensive analysis of a novel antipsychotic called lumateperone, marketed as Caplyta. Lumateperone gained FDA approval in 2019 for treating schizophrenia and later, in 2021, for treating bipolar depression. The review begins by delving into lumateperone's mechanism of action, which involves the partial agonism of the dopamine D2 receptor as well as its unique effects on the dopamine transporter, N-methyl-D-aspartate (NMDA) receptor, and serotonin transporter. Additionally, the study examines lumateperone's distinctive pharmacokinetics. Moreover, this review assesses lumateperone's metabolic profile and highlights its favorable outcomes regarding mean body weight, BMI, and waist circumference, surpassing those of other second-generation antipsychotic medications. The study explicitly emphasizes the efficacy and safety of lumateperone in treating schizophrenia and bipolar depression associated with bipolar I and II disorders. An extensive investigation of multiple clinical trials provides compelling evidence of lumateperone's advantages over existing antipsychotic medications. The review also acknowledges the limitations of lumateperone compared to other antipsychotics. In conclusion, this drug review underscores the importance of further research to uncover the additional limitations of lumateperone while acknowledging its promising benefits and potential for advancing treatment options. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Tarzian et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|